Peripheral/Endo

Caelum Biosciences Announces Two Oral Presentations of Additional Data from Phase 1b Study of Anti-Amyloid mAb CAEL-101 and Preclinical Imaging Study at 60th American Society of Hematology Annual Meeting

NEW YORK, Dec. 04, 2018 (GLOBE NEWSWIRE) — Caelum Biosciences, Inc. (“Caelum”), a company focused on developing treatments for rare and life-threatening diseases, today announced additional global longitudinal strain (“GLS”) data from the Phase 1b study of CAEL-101, a light chain fibril-reactive monoclonal antibody (“mAb”) 11-1F4, in patients with cardiac amyloid light […]

Arizona Patients Successfully Receive the World’s First Bioconvertible IVC Filter Commercially Offered In US

BTG plc (LSE: BTG), the global healthcare company, today announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device – the world’s first bioconvertible IVC filter. The BTG Sentry filter is designed to provide protection from Pulmonary Embolism (PE) for the period […]

Cardinal Health Announces FDA Approval of the INCRAFT® AAA Stent Graft System

DUBLIN, Ohio, November 28, 2018 — Cordis, a Cardinal Health company (NYSE: CAH), today announced that the U.S. Food and Drug Administration (FDA) has approved its INCRAFT® AAA Stent Graft System for use in complex access anatomies. The INCRAFT system is an ultra-low profile and flexible endovascular aneurysm repair (EVAR) system designed […]

MERIT MEDICAL RECEIVES 510(K) APPROVAL FOR EMBOCUBE EMBOLIZATION GELATIN FOR EMBOLIZATION OF HYPERVASCULAR TUMORS

SOUTH JORDAN, Utah – November 29, 2018 – Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in interventional, diagnostic and therapeutic procedures, announces that it has received 510(k) clearance for EmboCube Embolization Gelatin. EmboCube is indicated for use in embolization of hypervascular tumors. The […]

InspireMD Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard™ EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)

TEL AVIV, Israel, Nov. 29, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced details from several presentations of updated CGuard™ EPS data at the recent VEITHsymposium […]

Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal

CALGARY, Alberta, Nov. 28, 2018 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone downregulates factors and pathways associated with vascular calcification” in Atherosclerosis, the official peer-reviewed scientific journal of the European Atherosclerosis Society. “Apabetalone and its unique mechanism […]

InspireMD Announces Regulatory and Reimbursement Approval of CGuard™ Embolic Prevention System in Australia

TEL AVIV, Israel, Nov. 28, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that its novel CGuard™ Embolic Prevention System (EPS) has been granted regulatory approval […]

Boston Scientific Announces Recommended Offer to Acquire BTG plc.

MARLBOROUGH, Mass., Nov. 20, 2018 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced it has reached an agreement on the terms of a recommended offer to acquire BTG plc. (LSE: BTG), a company headquartered in the United Kingdom, which develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well […]

Hancock Jaffe Updates Status of Application to INVIMA for First-In-Human VenoValve Trial in Colombia

IRVINE, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has received an update from INVIMA (the Colombian equivalent of the U.S. FDA) in Bogota on the status of […]

Endologix Honors Innovators of Aortic Therapy at VEITHsymposium

IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today honored four innovators of aortic therapy at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium®), a meeting of endovascular specialists highlighting developments in the treatment of vascular disease. At an […]